Literature DB >> 26705669

Small data sets to develop and validate prognostic models are problematic.

Gary S Collins1, Yannick Le Manach2.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 26705669     DOI: 10.1016/j.ejca.2015.09.025

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  4 in total

1.  Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer.

Authors:  Ahmad Y Abuhelwa; Ganessan Kichenadasse; Ross A McKinnon; Andrew Rowland; Ashley M Hopkins; Michael J Sorich
Journal:  Cancers (Basel)       Date:  2021-04-21       Impact factor: 6.639

Review 2.  Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.

Authors:  Ashley M Hopkins; Andrew Rowland; Ganessan Kichenadasse; Michael D Wiese; Howard Gurney; Ross A McKinnon; Chris S Karapetis; Michael J Sorich
Journal:  Br J Cancer       Date:  2017-08-24       Impact factor: 7.640

3.  Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.

Authors:  Xi Wang; Bo Zhang; Xuelian Chen; Hongnan Mo; Dawei Wu; Bo Lan; Qun Li; Binghe Xu; Jing Huang
Journal:  Thorac Cancer       Date:  2019-04-24       Impact factor: 3.500

4.  Incorporating spatial dose metrics in machine learning-based normal tissue complication probability (NTCP) models of severe acute dysphagia resulting from head and neck radiotherapy.

Authors:  Jamie Dean; Kee Wong; Hiram Gay; Liam Welsh; Ann-Britt Jones; Ulricke Schick; Jung Hun Oh; Aditya Apte; Kate Newbold; Shreerang Bhide; Kevin Harrington; Joseph Deasy; Christopher Nutting; Sarah Gulliford
Journal:  Clin Transl Radiat Oncol       Date:  2017-11-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.